Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849187 | PMC |
| http://dx.doi.org/10.1128/JCM.02262-21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
Vaccine
February 2024
Dhirubhai Ambani Life Sciences Centre, Reliance Life Sciences Pvt. Ltd., Rabale, Navi Mumbai 400701, India. Electronic address:
SARS-CoV-2, severe acute respiratory syndrome coronavirus-2, causes coronavirus disease- 2019 (COVID-19). Mostly, COVID-19 causes respiratory symptoms that can resemble those of a cold, the flu, or pneumonia. COVID-19 may harm more than just lungs and respiratory systems.
View Article and Find Full Text PDF[Diagnostic performance of two antigen-tests compared to one PCR-Test to detect SARS-CoV-2 in an emergency department and emergency service].
Anaesthesiologie
November 2023
Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Deutschland.
Background: In the German hospital landscape and emergency care the COVID-19 pandemic was a stress test. Emergency medical health care in Germany is ensured by the supply chain between prehospital emergency rescue and clinical emergency care in the emergency rooms. In hospitals and emergency care settings a rapid, simple, accurate, and cost-effective test is needed to identify SARS-CoV‑2.
View Article and Find Full Text PDFStimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
Vaccines (Basel)
September 2023
Division of Infectious Diseases, City of Hope National Medical Center, Duarte, CA 91010, USA.
Hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell patients are immunocompromised, remain at high risk following SARS-CoV-2 infection, and are less likely than immunocompetent individuals to respond to vaccination. As part of the safety lead-in portion of a phase 2 clinical trial in patients post HCT/CAR-T for hematological malignancies (HM), we tested the immunogenicity of the synthetic modified vaccinia Ankara-based COVID-19 vaccine COH04S1 co-expressing spike (S) and nucleocapsid (N) antigens. Thirteen patients were vaccinated 3-12 months post HCT/CAR-T with two to four doses of COH04S1.
View Article and Find Full Text PDFExpanding the application of graphene vertical devices to dual femtomolar detection of SARS-CoV-2 receptor binding domain in serum and saliva.
Biosens Bioelectron
November 2023
São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, 13560-970, Brazil. Electronic address:
The emergence of the graphene-based hybrid electrical-electrochemical vertical device (EEVD) has introduced a promising nanostructured biosensor tailored for point-of-care applications. In this study, we present an innovative EEVD capable of simultaneously detecting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein in both serum and saliva. The foundation of the EEVD lies in a poly-neutral red-graphene heterojunction, which has been enhanced with a bioconjugate of gold nanoparticles and antibodies.
View Article and Find Full Text PDFDevelopment of an instrument-free and low-cost ELISA dot-blot test to detect antibodies against SARS-CoV-2.
Open Life Sci
August 2023
Facultad de Farmacia, Instituto de Investigaciones Farmacéuticas (INIFAR), Universidad de Costa Rica, San José, Costa Rica.
Article Synopsis
- Many labs use ELISA or CLIA tests to find anti-SARS-CoV-2 antibodies, but these methods require equipment that isn’t available in many low- and middle-income countries.
- A new dual antigen ELISA dot-blot test is introduced, offering high sensitivity and specificity to detect anti-SARS-CoV-2 IgG antibodies, and it can be done with minimal equipment in just one hour.
- This new test is also more affordable than existing rapid tests, making it a practical option for seroprevalence surveys in areas without access to advanced immunoassay facilities.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!